Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Silo Pharma, Inc. - Common Stock
(NQ:
SILO
)
6.315
+0.055 (+0.88%)
Streaming Delayed Price
Updated: 10:06 AM EDT, Jun 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Silo Pharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
↗
September 05, 2023
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Via
Benzinga
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
↗
August 28, 2023
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
↗
August 28, 2023
Via
Benzinga
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
↗
August 21, 2023
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds
Via
Benzinga
Topics
Cannabis
Economy
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
↗
August 14, 2023
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published
Via
Benzinga
Breaking Ground In Prevention & Relief Of Anxiety & PTSD: Silo Pharma' Nasal Formulation For Ketamine-Based Treatment
↗
August 08, 2023
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharma company merging traditional therapeutics with psychedelic research, has advanced the formulation development for its ketamine-composed drug...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
August 08, 2023
Via
Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
↗
August 03, 2023
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...
Via
Benzinga
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
↗
July 28, 2023
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023:
Via
Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
↗
July 04, 2023
World's Largest Psychedelics Conference Boasts 12K Attendees
Via
Benzinga
Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers
↗
June 22, 2023
This month, Silo Pharma (NASDAQ: SILO) announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia an
Via
Benzinga
Revolutionizing Rheumatoid Arthritis Treatment: Psychedelics Biotech Co. Touts New Patent
↗
June 21, 2023
Psychedelics-focused biopharmaceutical company Silo Pharma, Inc. (NASDAQ: SILO) announced on Wednesday that the U.S. Patent and Trademark Office has issued Patent 16/825,371 titled "Peptide-Targeted...
Via
Benzinga
Why Advanced Health Intelligence Shares Are Trading Higher By 111%; Here Are 20 Stocks Moving Premarket
↗
June 21, 2023
Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares gained 110.8% to $1.56 in pre-market trading after the company signed a Letter of Intention with UAE-Based e-script medicine management...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
June 21, 2023
It's time to start off the day with a breakdown of the biggest pre-market stock movers worth watching on Wednesday morning!
Via
InvestorPlace
Silo Pharma's New Ketamine Implant For Fibromyalgia And Chronic Pain Is In The Making
↗
June 13, 2023
Developmental-stage psychedelics biotech Silo Pharma (NASDAQ: SILO) has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant with...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
June 13, 2023
Via
Benzinga
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
↗
May 15, 2023
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths...
Via
Benzinga
Stress-Related Mood Disorders And Alzheimer's: Can This Patented Ketamine Drug Help?
↗
May 10, 2023
Silo Pharma Inc. (NASDAQ: SILO), one of the biotech companies developing next-generation psychedelic therapeutics, obtained a new US patent covering IP for its drug candidate SPC-15’s research and...
Via
Benzinga
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
↗
April 24, 2023
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...
Via
Benzinga
Stress, Anxiety, PTSD: 2 NASDAQ-Listed Drug Developers Advance Psychedelic-Inspired Meds
↗
April 20, 2023
Psychedelics biotech Silo Pharma Inc. (NASDAQ: SILO) and Columbia University are developing a novel compound formulation as a prophylactic treatment for stress, anxiety and PTSD.
Via
Benzinga
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
↗
April 05, 2023
Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin...
Via
Benzinga
Silo Pharma To Patent Novel Ketamine-Based Treatment For Chronic Condition
↗
March 27, 2023
Biopharma company Silo Pharma Inc.
Via
Benzinga
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
↗
March 20, 2023
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
March 21, 2023
On Tuesday, 74 companies achieved new lows for the year.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
March 20, 2023
Via
Benzinga
Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder
↗
March 15, 2023
Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions.
Via
Benzinga
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
↗
March 06, 2023
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
↗
February 27, 2023
During Monday's session, 56 companies made new 52-week lows.
Via
Benzinga
Silo Pharma, Mindset Pharma, Terran Biosciences Receive Psychedelic Treatments Patents, IP Portfolios Expanded
↗
February 03, 2023
Silo Pharma Sees Growth In IP With New US Patent For Novel Ketamine Method On Stress-Induced Affective Disorders
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
February 28, 2023
During Tuesday, 79 stocks hit new 52-week lows.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.